ClinicalTrials.gg
CompletedNCT00584298Updated May 8, 2009

Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide

A Phase 1 interventional study of SMS995 and Placebo in Irritable Bowel Syndrome (IBS), sponsored by Novartis. Completed at 7 sites in 4 countries. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-05-08.

Sponsored by Novartis · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies in Irritable Bowel Syndrome with a site in United Kingdom — 7 open to participants now, 8 under way, none of them phase 3. Irritable Bowel Syndrome · United Kingdom.

Enrollment
36th of 58
50 · median 71
Started
2008
with 2 others
Phase 1
Only one
of the 66
Registered
9th of 66
by date

Among the 66 studies in Irritable Bowel Syndrome with a site in United Kingdom, this one is the 36th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2008, is the only one in phase 1, and was the 9th registered.

Irritable Bowel Syndrome

1,119 studies on the registry are indexed under Irritable Bowel Syndrome; 210 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

7 of the 66 studies in Irritable Bowel Syndrome with a site in United Kingdom are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 129 Irritable Bowel Syndrome studies recruiting now, 34 (26%) set no upper age limit and 85 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Irritable Bowel Syndrome with a site in United Kingdom, or all of them as a file.
02

Study summary

This study is designed to provide information on feasibility and reproducibility of barostat assessments of colorectal sensory functions and compliance and their pharmacological modulation

03

Conditions studied

  • Irritable Bowel Syndrome (IBS)

Keywords

  • Barostat
  • distention
  • IBS
  • irritable
  • bowel
  • syndrome
  • colorectal
  • sensation
  • modulation
  • reproducibility
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A positive diagnosis of IBS.
  • Subjects must either have been surgically sterilized, hysterectomized at least 6 months prior to screening, be or be using a double-barrier local
  • .
  • Able to communicate well with the investigator, to understand and comply with the requirements of the study. Understand and sign the written

Exclusion criteria

Exclusion Criteria:

  • History of or evidence for structural diseases/conditions that affect the gastrointestinal system.
  • Other diseases or conditions that in the opinion of the Investigator significantly affect colorectal sensitivity.
  • Evidence of occult blood at stool analysis, or history of rectal bleeding.
  • Using or planning to use drugs or agents during the study period that alter GI physiology and visceral perception.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    1

    Drug: SMS995

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • DrugSMS995

    Also known as: Octreotide, Sandostatin

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. - 5 sensory pressure thresholds [mmHg] from ascending method of limits (AML) barostat protocol. - 16 sensory intensity ratings from the random phasic distention (RPD) barostat protocol.

    Time frame: throughout the study

Secondary outcomes

  1. - colorectal compliance

    Time frame: throughout the study

07

Study locations

7 sites
  • Novartis Investigator Site
    Boston, Massachusetts 02215, United States
  • Novartis Investigator Site
    Rochester, Minnesota 55905, United States
  • Novartis Investigator Site
    Hamilton, Canada
  • Novartis Investigator Site
    Gothenburg, Sweden
  • Novartis Investigator Site
    London, United Kingdom
  • Novartis Investigator Site
    Manchester, United Kingdom
  • Novartis Investigator Site
    Nottingham, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008 and a primary completion of Apr 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2007
First posted
Jan 2, 2008
Start
Jan 2008
Primary completionActual
Apr 2009
Last update
May 8, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00584298
Lead sponsor
Novartis
First posted
Jan 2, 2008
Start date
Jan 2008
Primary completion
Apr 2009
Last update
May 8, 2009

Study contacts

NOVARTIS
principal investigator · Novartis investigator site

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion